News >

Expert Details Developments in MPN Paradigm

Caroline Seymour
Published: Tuesday, May 01, 2018

David S. Snyder, MD

David S. Snyder, MD
Ruxolitinib (Jakafi), the sole FDA-approved agent for the treatment of patients with myelofibrosis, though effective in reducing splenomegaly and mitigating constitutional symptoms, does not significantly or reliably reduce the molecular burden or prevent progression to acute leukemia, noted David S. Snyder, MD.

on Multiple Myeloma and Myeloproliferative Neoplasms, Snyder, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, detailed these mutations and discussed investigational treatments within the field of myeloproliferative neoplasms (MPNs).

OncLive: Please provide an overview of your presentation.

Snyder: The field of MPNs is hitting its stride with new molecular markers that are being defined. We know about the important driver mutations including, JAK2, CALR, and NPL. Now, we are learning more about the prognostic importance of secondary mutations. The hope is that some of these findings will lead to targeted therapies. That’s what led to ruxolitinib, the only FDA-approved drug [that was developed for myelofibrosis]. There are other JAK2 inhibitors in clinical trials, one of which is pacritinib.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication